NCT04525053|Completed
Dosimetric Validation of Scans Generated by GAN From Pre-therapeutic MRI in Stereotactic Cerebral Radiotherapy
SBRT-IRM
Loading search results
SBRT-IRM
Sponsor study identifier
observational
184
1 country
1
Study Start
July 16, 2020
Actual (reported)Primary Completion
August 17, 2020
Actual (reported)Study Completion
August 17, 2020
Actual (reported)Stereotactic radiotherapy (SRT) is being widely accepted as a treatment of choice for patients with a small number of brain metastases and an acceptable size, allowing a better target dose conformity resulting in high local control rates and better sparing of organs at risk. Currently, imaging for such a delivery technique requires both a recent magnetic resonance imaging (MRI) brain study for volume definition and a computed tomography (CT) scan for SRT planning. An MRI-only workflow could reduce the risk of misalignment between the two imaging modalities and shorten the delay of planning. Given the absence of a calibrated electronic density on MRI, the investigators aim to assess the equivalence of synthetic CTs generated by a generative adversarial network (GAN) for planning in the brain SRT setting.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 17, 2020
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 16, 2020
Actual (reported)August 17, 2020
Actual (reported)August 17, 2020
Actual (reported)August 17, 2020
Actual (reported)August 25, 2020
Actual (reported)Local Gamma Analysis Passing Rate
To be considered as comparable, 2 dose maps must have a Local Gamma Analysis Passing Rate higher than 98%. The primary outcome measure will be to compare the Local Gamma Analysis Passing Rate between the 2 dose maps (one initial dosimetric planification and one dosimetric planification extracted from the synthetic ct scan).
Once, at the time of treatment delivery
Global Gamma Analysis Passing Rate
Once, at the time of treatment delivery
Planning Target Volume's coverage values
Once, at the time of treatment delivery
Organs at risk Dose Constraints
Once, at the time of treatment delivery
Restrospective inclusion of all patients treated with intra-cranial SRT for brain metastases from 2014 to 2018 in our single institution
CHRU de Brest
Brest, 29609, France
184 participants (actual enrollment reported by the registry).
First Submitted
August 17, 2020
First Posted
August 25, 2020
Study Start
July 16, 2020
Actual (reported)ASL in Brain Metastasis MRI Following Gamma Knife Treatment
Magnetic Resonance Imaging-guided Adaptive Radiotherapy for Large Brain Metastases
Contact the study team to confirm eligibility.
Primary Completion
August 17, 2020
Actual (reported)Study Completion
August 17, 2020
Actual (reported)Last Updated
August 25, 2020
Record last verified: 2020-08
All collected data that underlie results in a publication.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: